COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA.
AuthorVilches, Thomas N
Moghadas, Seyed M
Fitzpatrick, Meagan C
Hotez, Peter J
Schneider, Eric C
Galvani, Alison P
JournalLancet Regional Health. Americas
MetadataShow full item record
AbstractBackground: The fourth wave of COVID-19 pandemic peaked in the US at 160,000 daily cases, concentrated primarily in southern states. As the Delta variant has continued to spread, we evaluated the impact of accelerated vaccination on reducing hospitalization and deaths across northeastern and southern regions of the US census divisions. Methods: We used an age-stratified agent-based model of COVID-19 to simulate outbreaks in all states within two U.S. regions. The model was calibrated using reported incidence in each state from October 1, 2020 to August 31, 2021, and parameterized with characteristics of the circulating SARS-CoV-2 variants and state-specific daily vaccination rate. We then projected the number of infections, hospitalizations, and deaths that would be averted between September 2021 and the end of March 2022 if the states increased their daily vaccination rate by 20 or 50% compared to maintaining the status quo pace observed during August 2021. Findings: A 50% increase in daily vaccine doses administered to previously unvaccinated individuals is projected to prevent a total of 30,727 hospitalizations and 11,937 deaths in the two regions between September 2021 and the end of March 2022. Southern states were projected to have a higher weighted average number of hospitalizations averted (18.8) and lives saved (8.3) per 100,000 population, compared to the weighted average of hospitalizations (12.4) and deaths (2.7) averted in northeastern states. On a per capita basis, a 50% increase in daily vaccinations is expected to avert the most hospitalizations in Kentucky (56.7 hospitalizations per 100,000 averted with 95% CrI: 45.56 - 69.9) and prevent the most deaths in Mississippi, (22.1 deaths per 100,000 population prevented with 95% CrI: 18.0 - 26.9). Interpretation: Accelerating progress to population-level immunity by raising the daily pace of vaccination would prevent substantial hospitalizations and deaths in the US, even in those states that have passed a Delta-driven peak in infections. Funding: This study was supported by The Commonwealth Fund. SMM acknowledges the support from the Canadian Institutes of Health Research [OV4 - 170643, COVID-19 Rapid Research] and the Natural Sciences and Engineering Research Council of Canada, Emerging Infectious Disease Modelling, MfPH grant. MCF acknowledges support from the National Institutes of Health (5 K01 AI141576).
Rights/Terms© 2021 The Authors.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/17643
- Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study.
- Authors: Shoukat A, Vilches TN, Moghadas SM, Sah P, Schneider EC, Shaff J, Ternier A, Chokshi DA, Galvani AP
- Issue date: 2022 Jan
- Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19)
- Authors: Aleem A, Akbar Samad AB, Slenker AK
- Issue date: 2022 Jan
- Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants.
- Authors: Sah P, Vilches TN, Moghadas SM, Fitzpatrick MC, Singer BH, Hotez PJ, Galvani AP
- Issue date: 2021 May
- COVID-19 Vaccination and Estimated Public Health Impact in California.
- Authors: Tan ST, Park HJ, Rodríguez-Barraquer I, Rutherford GW, Bibbins-Domingo K, Schechter R, Lo NC
- Issue date: 2022 Apr 1
- Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
- Authors: Sonabend R, Whittles LK, Imai N, Perez-Guzman PN, Knock ES, Rawson T, Gaythorpe KAM, Djaafara BA, Hinsley W, FitzJohn RG, Lees JA, Kanapram DT, Volz EM, Ghani AC, Ferguson NM, Baguelin M, Cori A
- Issue date: 2021 Nov 13